Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

FLAMINGO-01 is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2/neu positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment.
[Greenwich LifeSciences, Inc.]
Press Release
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News